Adjuvant Targeted Therapy and Molecular Testing in Early-Stage NSCLC

This segment reviews data on adjuvant targeted therapy for RET fusion-positive NSCLC in patients treated with curative-intent surgery, with faculty discussing the strongly positive phase 3 results and their clinical implications. The panel emphasizes that these findings reinforce the importance of comprehensive molecular profiling for all early-stage patients rather than limited panels. Discussion addresses practical testing considerations, including the growing role of ctDNA-based approaches and turnaround time, and how prior neoadjuvant chemoimmunotherapy factors into adjuvant targeted therapy decisions. Faculty explore the persistent question of optimal treatment duration, the arbitrariness of current fixed durations, and the potential for MRD testing and risk stratification to personalize how long patients remain on adjuvant therapy.